Abstract:
We describe a Flt-1 decoy comprising a VEGF binding domain of Flt-1 and a membrane anchoring domain, in which the Flt-1 decoy does not substantially comprise an intracellular domain.
Abstract:
There is provided an attachment configured to detachably couple to a fluid extruding device, the attachment comprising: a membrane having a plurality of pores configured to allow a cell to pass through while inducing a mechanical stress to the cell such that the introduction of one or more substances into the cell is facilitated; and an engaging member for coupling to the outlet of the fluid extruding device such that the membrane is in fluid communication with the outlet of the fluid extruding device, wherein the fluid extruding device is configured to extrude fluid via mechanical actuation.
Abstract:
There is provided a compound comprising at least two ligands that are individually coupled to a linker, wherein each ligand is independently selected from the group consisting of a substituted benzylguanine derivative, a substituted benzylcytosine derivative, a haloalkyl moiety, a drug, a peptide, a hormone, an inorganic compound and a protein. The compound may be part of an oligomer. The compound may be employed in a method of dimerizing a pair of proteins, which may alter a biological function in a cell. There is also provided a method of forming the compound.
Abstract:
The present invention relates to an isolated mirtron capable of binding a target nucleic acid, wherein the isolated mirtron comprises: a) a stem loop structure comprising a 5′ splice site, b) a tail sequence comprising a 3′ splice site and a polypyrimidine-comprising sequence, and c) a branch point sequence. Further, the present invention relates to vectors and pharmaceutical compositions comprising such mirtrons as well as methods of treating a disease comprising administering such pharmaceutical compositions.